These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19450092)

  • 21. New avenues for second-line treatment of metastatic non-small-cell lung cancer.
    Gridelli C; Maione P; Rossi A; Falanga M; Bareschino M; Schettino C; Colantuoni G; Guerriero C; Nicolella D; Rossi E; Ferrara ML; Palazzolo G
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):115-24. PubMed ID: 19105711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erlotinib for the treatment of relapsed non-small cell lung cancer.
    McLeod C; Bagust A; Boland A; Hockenhull J; Dundar Y; Proudlove C; Davis H; Green J; Macbeth F; Stevenson J; Walley T; Dickson R
    Health Technol Assess; 2009 Jun; 13 Suppl 1():41-7. PubMed ID: 19567213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
    J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world.
    Lin CC; Hsia TC; Chien CR
    Lung Cancer; 2012 Jun; 76(3):499-500. PubMed ID: 22503286
    [No Abstract]   [Full Text] [Related]  

  • 26. Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence.
    Carlson JJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):409-16. PubMed ID: 19817524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
    Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
    J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
    Borget I; Cadranel J; Pignon JP; Quoix E; Coudert B; Westeel V; Dansin E; Madelaine J; Madroszyk A; Friard S; Daniel C; Morin F; Chouaid C;
    Eur Respir J; 2012 Jan; 39(1):172-9. PubMed ID: 21659409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and economic review of erlotinib in non-small-cell lung cancer.
    Yeung K; Carlson JJ
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):411-23. PubMed ID: 22971028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.
    Cohen MH; Johnson JR; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005; 10(6):363-8. PubMed ID: 15967829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Budget impact analysis of pemetrexed introduction: case study from a teaching hospital perspective, Thailand.
    Chanjaruporn F; Roughead EE; Sooksriwong CO; Kaojarern S
    J Med Assoc Thai; 2011 Sep; 94(9):1026-34. PubMed ID: 21970190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-line treatment for non-small-cell lung cancer: one size does not fit all.
    Caponi S; Vasile E; Ginocchi L; Tibaldi C; Borghi F; D'Incecco A; Lucchesi M; Caparello C; Andreuccetti M; Falcone A
    Clin Lung Cancer; 2010 Sep; 11(5):320-7. PubMed ID: 20837457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies.
    de Marinis F; De Santis S; De Petris L
    Semin Oncol; 2006 Feb; 33(1 Suppl 1):S17-24. PubMed ID: 16472705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.
    Chung FT; Lee KY; Fang YF; Shieh MH; Lin SM; Yu CT; Lo YL; Lin TY; Kuo CH; Feng PH; Ni YL; Kuo HP
    Chemotherapy; 2011; 57(2):147-55. PubMed ID: 21454972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
    Manson GV; Ma PC
    Clin Lung Cancer; 2010 Jan; 11(1):57-60. PubMed ID: 20085869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
    Ramalingam S; Sandler AB
    Oncologist; 2006 Jun; 11(6):655-65. PubMed ID: 16794244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Maintenance treatment of non-small cell lung cancer].
    Hansen O; Schytte T
    Ugeskr Laeger; 2010 Mar; 172(12):954. PubMed ID: 20334788
    [No Abstract]   [Full Text] [Related]  

  • 39. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).
    Carlson JJ; Reyes C; Oestreicher N; Lubeck D; Ramsey SD; Veenstra DL
    Lung Cancer; 2008 Sep; 61(3):405-15. PubMed ID: 18295368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.